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Kupffer cellPlatelets are reportedly causal in hepatitis. We previously showed that in mice, lipopolysaccharide (LPS)
induces a reversible and macrophage-dependent hepatic platelet accumulation (HPA), including transloca-
tion of platelets into Disse spaces and their entry into hepatocytes. Concanavalin A (ConA), which induces
hepatitis in mice via both T cells and macrophages, also induces HPA. Here, we examined the relationship
between HPA and ConA-hepatitis. ConA-hepatitis and HPA were evaluated by serum transaminases, hepatic
5-hydroxytryptamine, and/or electron microscopy. Unlike LPS-induced HPA, ConA-induced HPA was only
moderately dependent on phagocytic macrophages. Against expectations, platelet-depletion signiﬁcantly
exacerbated ConA-hepatitis, and anti-P-selectin antibody and P-selectin receptor blockade reduced both
ConA-induced HPA and hepatitis. Prior induction of HPA by pretreatment with low-dose LPS powerfully
reduced ConA-hepatitis. Such protection by LPS-pretreatment was not effective in mice depleted of
phagocytic macrophages. In platelet-depleted mice, LPS-pretreatment severely exacerbated ConA-hepatitis.
In mice depleted of both macrophages and platelets, neither ConA nor LPS-pretreatment+ConA induced
hepatitis. In mice deﬁcient in IL-1α and IL-1β (but not in TNFα), ConA-induced hepatitis was mild, and a
protective effect of LPS was not detected. These results suggest that (i) there are causal and protective types of
HPA, (ii) the causal type involves hepatic aggregation of platelets, which may be induced by platelet
stimulants leaked from injured hepatocytes, (iii) the protective type is inducible by administration of prior
low-dose LPS in amanner dependent on phagocytic (or F4/80-positive) macrophages, and (iv) IL-1 is involved
in both the causal and protective types.l rights reserved.© 2011 Elsevier B.V. All rights reserved.1. Introduction
Increasing evidence suggests that in addition to their roles in
various inﬂammatory diseases, platelets are important in defending
the host against invasion by foreign organisms [1–4]. We previously
found that at low doses, lipopolysaccharide (LPS) induces hepatic
platelet accumulation (HPA) in mice, an effect that can be assessed by
measuring the 5-hydroxytryptamine (5HT) level [1,5–7]. In such LPS-
induced HPA, translocation of platelets into Disse spaces and their
entry into hepatocyte are frequently observed [8]. The LPS-induced
HPA can be largely prevented by prior depletion of phagocytic, F4/80-
positive macrophages (or Kupffer cells) [8]. We have also reported
that concanavalin A (ConA), too, induces a marked increase in hepatic
5HT [1,5,6], although it has not been established whether this 5HT
accumulation is indeed a reﬂection of HPA.There are several murine hepatitis models [induced by, for
example, injection of LPS after Propionibacterium acnes treatment,
co-injection of LPS plus D-galactosamine (GalN), or injection of ConA
alone]. It is generally recognized that ConA-induced hepatitis is T cell-
mediated, because nude mice (mostly deﬁcient in mature T-cells) are
resistant to ConA-hepatitis [9]. On the other hand, both the hepatitis
induced by P. acnes+LPS and that induced by GalN+LPS are
mediated by macrophages (via production of inﬂammatory cyto-
kines) [10–13]. However, it has been repeatedly reported that
macrophage-depletion markedly reduces ConA-hepatitis [14–16],
suggesting that in addition to T-cells, macrophages too are causally
involved in ConA-hepatitis.
Platelet-depletion reportedly affords signiﬁcant protection against
the mortality induced by GalN+LPS [17], and indeed activation of
platelets occurs in the hepatitis models induced by either GalN+TNF
or ConA [18,19]. Actually, GalN+LPS induces a marked HPA that
precedes the development of severe congestion [20]. These results are
all indicative of platelets playing causal roles in those hepatitis
models, irrespective of whether the hepatitis is T cell-mediated or
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are protective in Fas-mediated hepatitis, when the hepatitis is local or
not severe [21]. A very interesting point to note is that although LPS
induces HPA, as described above, LPS-pretreatment has been shown to
protectmice against the hepatitis induced by either ConA or GalN+LPS
[21–25]. As yet, the precise mechanisms underlying this protection
remain unclear.
The above background led us to speculate that platelets or HPA
might be involved in the development of hepatitis, but that a pre-
accumulation of platelets in the liver (i.e., HPA) resulting from low-
dose LPS-pretreatmentmightmodulate this process. Here, inmice, we
examined the relation between platelets and ConA-induced hepatitis
and between platelets and the protective effects of LPS-pretreatment.2. Materials and methods
2.1. Animals
Male BALB/c mice (6–7 weeks old) were used in experiments.
BALB/c mice deﬁcient in IL-1α, IL-1β, and/or TNFα were established
as reported previously [26,27] and raised in our laboratory. All
experiments conformed to national requirements (Japanese law no.
105, notiﬁcation no. 6) and complied with the Guidelines for Care and
Use of Laboratory Animals in Tohoku University.2.2. Materials
ConA, clodronate, low-molecular-weight heparin (LMWH), and
LPS from Escherichia coli O55:B5 were obtained from Sigma (St. Louis,
MO, USA). ConA and LPS were dissolved in sterile saline. Hybridoma
cells producing a rat monoclonal anti-mouse platelet antibody, Pm-1,
were provided by Dr. Todokoro (RIKEN, Tsukuba, Japan) [28]. Pm-1
antibody (IgG fraction) was prepared by precipitation with ammoni-
um sulfate and dialysis of the precipitant. MWReg30 [a rat
monoclonal anti-mouse integrin αIIb (CD41) antibody] and anti-P-
selectin antibody were obtained from BD Pharmingen (San Jose, CA,
USA). Normal rat IgG was used as a control for these antibodies.
Recombinant human IL-1α and human IL-1β were provided by
Dainippon Pharmaceutical Co. (Osaka, Japan) and Ohtsuka Pharma-
ceutical Co. (Tokushima, Japan), respectively. Unless otherwise
mentioned, reagents were injected intravenously (i.v.) via a caudal
vein.2.3. Platelet count and estimation of HPA
Platelets were counted as described previously [21], and HPA was
assessed by a method involving the use of 5HT as a marker for
platelets [21,29,30].2.4. Depletion and detection of platelets and phagocytic macrophages
Clodronate-encapsulated liposomes (Clo-lip) speciﬁcally deplete
phagocytic macrophages [31,32]. The “original suspension” of Clo-lip
was prepared as described previously [33]. Five-fold-diluted (with saline)
original Clo-lip suspension was intravenously injected (0.2 ml/mouse) to
eliminate F4/80-positive cells (macrophages) from the liver [34].
Macrophages were detected by immunohistochemical staining using an
F4/80 antibody (Serotec, Kidlington, UK) as described previously [33].
Platelets were depleted either by a subcutaneous (s.c.) injection of Pm-1
(10 mg/kg) or by an i.v. injection of MWReg30 (0.2 mg/kg) [35]. Platelets
in the liver were detected by immunohistochemical staining with Pm-1
[36].2.5. Determination of hepatitis markers
Blood (several drops) was collected directly from the neck into test
tubes after decapitation, and aspartate aminotransferase (AST) and
alanine aminotransferase (ALT) activities in the plasma were measured
photometrically using commercial kits (Wako Pure Chemical Ind., Osaka,
Japan).
2.6. Electron microscopy
Livers were removed rapidly from decapitated mice. In normal
mice and all experimental groups of mice, 50–60% of the total blood
was removed by the decapitation. The liver was chopped into small
pieces (about 10 mm3), and the specimens were ﬁxed in a mixture of
2.5% glutaraldehyde and 2% paraformaldehyde in 0.1 M sodium
cocodylate buffer (pH 7.4). After a thorough rinsewith PBS, specimens
were post-ﬁxed in 2% osmium tetraoxide, dehydrated through a
graded series ethanol, passed through propylene oxide, and then
embedded in EPON 812. Ultra-thin sections were stained with uranyl
acetate and lead citrate. In this study, we did not use perfusion ﬁxation
because the perfusion would have removed blood, and therefore
platelets, from the sinusoidal capillaries in the liver.
2.7. Data analysis
Experimental values are given as mean±standard deviation (SD).
Unless otherwise mentioned, each value is the mean±SD from 5
mice. The statistical signiﬁcance of differences was analyzed using
Dunnett's multiple-comparison test, P values less than 0.05 being
considered to indicate signiﬁcance.
3. Results
3.1. ConA-induced increase in liver 5HT reﬂects HPA
ConA induced an increase in liver 5HT that peaked at around 6 h,
preceding the peak in the hepatitis markers AST and ALT (Fig. 1A). ConA
induced this increase even at 5 mg/kg (Fig. 1B), a dose that did not
increase the two hepatitis markers (data not shown). If the increase in
liver 5HT were due to an accumulation of 5HT itself (i.e., not platelets),
pargyline (an irreversible inhibitor of the 5HT-metabolizing enzyme,
monoamine oxidase) might be expected to augment it [37]. However,
pargyline did not have such an effect in mice given ConA (data not
shown). Histochemical staining using Pm-1 conﬁrmed that platelet
accumulationwas localized around sinusoidal vessels in the livers ofmice
given ConA (Fig. 1C). These results suggest that (i) the hepatic 5HT
increase is indeed a reﬂection of HPA, (ii) ConA induces HPA at low doses
without inducing hepatitis, and (iii) the ConA-induced HPA peaks before
the peak increases in hepatitis markers.
3.2. Depletion of neither platelets nor phagocytic macrophages affects
hepatitis markers
Subcutaneous injection of Pm-1 (10 mg/kg) largely depleted
platelets from the blood within 12 h (Fig. 2A). The platelet count and
5HT level in the blood decreased in parallel, supporting the notion that
5HT is a marker for platelets (and thus for HPA). At 24 h after the Pm-1
injection, the levels of platelets and5HT in thebloodwere less than5%of
their initial levels. The transient 5HT increase in the liver (Fig. 2A) may
suggest that damaged (or stimulated) platelets are transiently trapped
in the liver during the course of their degradation. Despite this profound
thrombocytopenia, there was no apparent illness in the mice, and the
platelet levels recovered progressively (starting 3 days after the Pm-1
injection) (data not shown). Control IgG (10 mg/kg, s.c.) produced no
signiﬁcant changes in the basal levels of platelets and 5HT (data not
shown). In control mice (saline-injected), F4/80-positive cells are seen
Fig. 1. Effects of ConA. (A) Time-dependent changes in hepatic 5HT and in serum AST and ALT activities. ConA (10 or 30 mg/kg) was injected at time 0, and the livers and blood were
taken at the times indicated. (B) Dose-dependent increases in hepatic 5HT. ConA was injected at the doses indicated, and livers were taken 6 h later. (C) Histochemical detection of
HPA in mice given ConA. Livers were taken 6 h after injection of ConA (5 mg/kg), subjected to immunostaining using an anti-mouse platelet monoclonal antibody (Pm-1), and
visualized using ﬂuorescein isothiocyanate (green ﬂuorescence) or diaminobenzidine (brown spots). Results shown in C are representative of 5 mice.
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eliminated F4/80-positive cells from the liver within 24 h of the
injection (i.e., no F4/80-positive cells were detected) (Fig. 2B). The
phagocytic macrophage-depleted mice looked completely healthy, and
therewasnoapparent change in their activities.Weused saline-injected
mice as a control because liposomes containing saline alone modulate
the responses of macrophages [32]. Injection of Pm-1 mostly (95% or
more) depleted the liver of 5HT (Fig. 2C), indicating that the basal level
of liver 5HT is also due to the presence of platelets. The absence ofFig. 2. Depletions of platelets and macrophages. (A) Effects of Pm-1 on platelets and on 5HT
the indicated times. (B) Effects of Clo-lip on macrophages. Saline or Clo-lip was injected, an
antibody, and visualized using diaminobenzidine (brown spots). Results shown are represen
Saline, Pm-1, or Clo-lip was injected as described above, and 24 h later blood and livers weplatelets in livers 24 h after the injection of Pm-1was also conﬁrmed by
electron-microscopic observations (see Section 3.13). Neither Pm-1 nor
Clo-lip by themselves affected AST or ALT, and Clo-lip had no signiﬁcant
effect on the basal 5HT level in the liver (Fig. 2C).
3.3. ConA-induced HPA is partially phagocytic macrophage-dependent
In the following experiments, an increase in liver 5HT is termed
“HPA” for convenience. In Clo-lip-treated mice, the ConA-induced HPAin blood and liver. Pm-1 was injected (s.c.) at time 0, and blood and livers were taken at
d 24 h later livers were taken. The livers were subjected to immunostaining with F4/80
tative of three mice. (C) Effects of Pm-1 and Clo-lip on liver 5HT and hepatitis markers.
re taken.
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Introduction, LPS also induced HPA (Fig. 3B), and as previously reported
[8] the LPS-induced HPA was largely prevented by Clo-lip-pretreatment
(Fig. 3B). These results suggest that although both LPS and ConA induce
HPA, the LPS-induced HPA is largely phagocytic macrophage-dependent,
while the ConA-induced HPA is moderately phagocytic macrophage-
dependent (i.e., the latter is less dependent on phagocytic macrophages
than the former).3.4. LPS-pretreatment reduces ConA-induced hepatitis and HPA
It should be noted that LPS by itself (at 0.1 mg/kg or less) did not
increase AST or ALT in the blood (data not shown). On the contrary, as
described in Introduction, LPS-pretreatment reportedly reduces
ConA-hepatitis. Thus, if HPA is causal for hepatitis, LPS-pretreatment
might be expected to reduce ConA-induced HPA. Indeed, LPS-
pretreatment markedly reduced ConA-induced HPA (Fig. 3C), sug-
gesting that platelets are causally involved in ConA-hepatitis, and
that prior depletion of platelets may be protective against such
hepatitis.3.5. Platelets are not causal for ConA-hepatitis, but phagocytic macrophages
are
However, contrary to the above expectation, Pm-1 (i.e., platelet-
depletion) slightly, but signiﬁcantly, augmented the ConA-induced
increase in AST, although it had no signiﬁcant effect on ALT (Fig. 4A). In
contrast, Clo-lip (i.e., phagocytic macrophage-depletion) reduced the
ConA-induced HPA (Figs. 3A and 4A) and dramatically reduced the
effect of ConA on hepatitis markers (Fig. 4A). In mice depleted of both
phagocytic macrophages and platelets, the ConA-induced increases in
hepatitis markers were minimal (Fig. 4B). These results suggest that
contrary to our initial expectation, platelets are not causal, and instead
macrophages are critically important for the development of ConA-
hepatitis.Fig. 3. Effects of macrophage-depletion and LPS-pretreatment on the HPA induced by ConA o
livers were taken at the indicated times. (B) S or Clo-lip was injected, followed 24 h later by
(C) S or LPS (10 μg/kg) was injected, followed 2 h later by injection of S, ConA (30 mg/kg),3.6. LPS-pretreatment protects against ConA-hepatitis via phagocytic
macrophage-dependent HPA
As shown in Fig. 3B and C, a low dose of LPS (10 μg/kg) induces
HPA within a few hours of its injection in normal mice. Thus, in the
following experiments, we examined the effect of pretreatment with
10 μg/kg of LPS (i.e., the effect of a prior induction of HPA) on the
development of ConA-hepatitis.
The LPS-induced HPA was still detectable at 14 h after the LPS
injection (see S+LPS+S group in Fig. 5A). LPS markedly reduced the
ConA-induced HPA (Fig. 5A), and this reduction was repeatedly
conﬁrmed in other experiments (see Figs. 3C, 5B and 7B). In line with
previous reports (see Introduction), LPS-pretreatment was found to be
highly protective against ConA-induced hepatitis (see AST and ALT data
for the S+LPS+ConA group in Fig. 5A). In contrast, in phagocytic
macrophage-depleted mice (viz. the group given Clo-lip), LPS+ConA
induced a marked HPA, although LPS by itself did not induce HPA. In
addition, the protective effect of LPS-pretreatment observed in normal
mice was completely absent in these macrophage-depleted mice: i.e.,
the LPS+ConA-induced hepatitis in phagocytic macrophage-depleted
mice (Clo-lip+LPS+ConA) was quantitatively similar to that induced
by ConA alone in normal mice (S+S+ConA) (Fig. 5A). These results
suggest that (i) the protective effect of LPS-pretreatment is phagocytic
macrophage-dependent, and prior induction of HPAmay be involved in
this protection, and (ii) there might be a pathway by which LPS+ConA
induces hepatitis without the involvement of phagocytic macrophages
(see Discussion).3.7. LPS-pretreatment exacerbates ConA-hepatitis in platelet-depleted
mice
As shown in Fig. 4A, platelets themselves were not causal for
ConA-hepatitis (actually, they were slightly protective). Surprisingly,
in a pilot experiment in which platelet-depleted mice were injected
with LPS and then with ConA, the mice soon weakened, and some
mice (2/6) died within 6 h of the ConA injection. Thus, in the experimentr LPS. (A) ConA (30 mg/kg) was injected 24 h after injection of saline (S) or Clo-lip, and
injection of S or LPS (10 or 100 μg/kg). Livers were taken 4 h after the second injection.
or LPS (10 μg/kg). Blood and livers were taken 4.5 h after the second injection.
Fig. 4. Effects of depletion of platelets and/or macrophages. (A) Effects of depletion of either platelets or macrophages. Saline or ConA (30 mg/kg) was injected 24 h after injection of
S, Pm-1 (s.c.), or Clo-lip. Livers and bloodwere taken 12 h after the second injection. (B) Effects of depletion of both platelets andmacrophages. S or Pm-1was injected (s.c.), followed
12 h later by injection of S or Clo-lip. Finally, S or ConA (30 mg/kg) was injected 6 h after the second injection, and 12 h later livers and blood were taken.
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measurement-point employed inmost other experiments) after injection
of ConA. Even at this time-point, hepatitis markers were markedly
increased in the Pm-1+LPS+ConA group. These results (i) suggest that
LPS-pretreatment strongly exacerbates ConA-hepatitis in platelet-
depleted mice (in complete contrast to its protective effect in
normal mice), and (ii) support the above-described idea that the
protective effect of LPS in platelet-non-depleted mice depends
largely on platelets or HPA.Fig. 5. Effects of low-dose LPS-pretreatment. (A) Effects of LPS-pretreatment in macrophage-
LPS (10 μg/kg). Then, S or ConA (30 mg/kg) was injected 2 h after the second injection, and
mice. S or Pm-1 was injected (s.c.), followed 24 h later by injection of S or LPS (10 μg/kg). Th
and blood were taken.3.8. In mice depleted of both phagocytic macrophages and platelets,
ConA with LPS-pretreatment induces no signiﬁcant hepatitis
As described above, LPS+ConA induces both hepatitis and HPA in
phagocytic macrophage-depleted mice (Fig. 5A), and this combina-
tion strongly exacerbates ConA-hepatitis in platelet-depleted mice
(Fig. 5B). In contrast to these effects, in mice depleted of both
phagocytic macrophages and platelets, LPS-pretreatment before ConA
injection exhibited no signiﬁcant hepatotoxic effect. This result, too,depleted mice. Saline (S) or Clo-lip was injected, followed 24 h later by injection of S or
12 h later livers and blood were taken. (B) Effects of LPS-treatment in platelet-depleted
en, S or ConA (30 mg/kg) was injected 2 h after the second injection, and 2 h later livers
Fig. 6. Effects of LPS-treatment inmice depleted of both platelets andmacrophages. Saline (S) or Pm-1was injected (s.c.), followed 12 h later by injection of S or Clo-lip. Then, S or LPS
(10 μg/kg) was injected 24 h after the second injection. Finally, S or ConA (30 mg/kg) was injected at 2 h after the third injection. Livers and blood were taken 12 h after the last
injection.
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are critically important for the induction of ConA-hepatitis, and
(ii) the protective effect of LPS-pretreatment depends largely on
platelets or HPA.3.9. Anti-αIIb antibody has essentially the same effects as Pm-1
To try to conﬁrm the effects of platelet-depletion on ConA-hepatitis
described above, we tested the effects of MWReg30, another monoclo-
nal anti-platelet antibody. This recognizes platelet-speciﬁc integrinαIIb
(CD41) and depletes platelets from the circulation [35]. Indeed, at the
dose used in the present study, MWReg30 reduced the platelet count to
about 30% of its normal level, but such treatmentwithMWReg30hadno
signiﬁcant effects on the ConA-induced increases in hepatitis markers
(Fig. 7A). However, in a pilot experiment, MWReg30-treated mice
becameseverelyweakenedwithin a fewhoursof ConA injection (as also
observed in Pm-1-treated mice). Thus, in the experiment shown in
Fig. 7B, we measured hepatitis markers at 4.5 h (not at 12 h as in most
other experiments) after injection of ConA. As also observed in mice
pretreatedwith Pm-1 (Fig. 5B), the ConA-induced increases in hepatitis
markers were powerfully augmented in mice pretreated with
MWReg30 (Fig. 7B). These results demonstrate that platelet-depletion,
whether by Pm-1 or by MWReg30, does indeed strongly exacerbate
ConA-hepatitis.Fig. 7. Effects of MW-Reg, another monoclonal anti-mouse platelet antibody. (A) Effects o
followed 24 h later by injection of S or ConA (30 mg/kg). Blood and livers were taken 12 h aft
MWReg30 was injected, followed 24 h later by injection of S or LPS (10 μg/kg). Then, S or Con
were taken.3.10. IL-1 is involved in ConA-induced hepatitis
We previously reported that among the cytokines tested, IL-1
(both α and β types) and TNFα (but not IL-2, IFNγ, IL-12, IL-8, G-CSF,
or GM-CSF) each induced HPA (or a hepatic 5HT increase) [8]. Hence,
we tested the effects of ConA in mice deﬁcient in IL-1 and/or TNFα.
The levels of the hepatitis markers induced by ConA in IL-1 KO mice
were signiﬁcantly lower than those induced by ConA in WT mice
(Fig. 8A), although there was no signiﬁcant difference between such
mice in their HPA levels. These results suggest that IL-1 is causally
involved in ConA-induced HPA and hepatitis.
3.11. IL-1 is also involved in LPS-induced protection against ConA-induced
hepatitis
We previously reported that IL-1 (but not TNFα, IL-2, IL-6, IL-12, or
IFNs) is protective against the hepatitis induced by LPS+GalN [23], and
that a very low dose of IL-1 (1 μg/kg) can induce a transient hepatic 5HT
increase (orHPA)within a fewhours of its intraperitoneal injection [38].
Thus, IL-1 might be expected to be involved in the protective effect of
LPS-pretreatment. Indeed, LPS was not effective in IL-1-KO mice
(Fig. 8B). Having obtained these results, we examined the effect of an
intraperitoneal injection of human recombinant IL-1α or IL-1β (0.001–
1 μg/kg, 0.5–2 h before ConA-injection). However, we failed to obtain a
protective effect of IL-1 like that induced by LPS-pretreatment (data notn platelets and hepatitis markers. Saline (S) or MWReg30 (0.2 mg/kg) was injected,
er the second injection. (B) Effects on the protection afforded by LPS-pretreatment. S or
A (30 mg/kg) was injected 2 h after the second injection, and 4.5 h later blood and livers
Fig. 8. Involvement of IL-1 in ConA-inducedHPA and hepatitis, and in the protective effect of LPS. (A) Effects of ConA inmice deﬁcient in IL-1 and/or TNFα. Saline (S) or ConA (30 mg/kg)
was injected into variousmice [viz. control BALB/cwild-type (WT)mice, IL-1-KOmice (deﬁcient inboth IL-1α and IL-1β), TNFα-KOmice, or triple-KO(TKO)mice (deﬁcient in IL-1α, IL-1β,
and TNFα)], and 12 h later livers and blood were taken. (B) Effects of LPS-pretreatment in IL-1-KO mice. S or LPS (10 μg/kg) was injected into WT or IL-1-KO mice, and 2 h later ConA
(30 mg/kg) was injected. Livers and blood were taken 12 h after the ConA injection.
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induced protection against ConA-induced hepatitis, exogenously ad-
ministered IL-1 may not be effective.
3.12. P-selectin is involved in ConA-induced HPA
P-Selectin (PS) is known to be expressed on the surface of activated
platelets and vascular endothelial cells [39]. Further, PS is reportedly [40]
involved in the development of ConA-hepatitis since: (i) PS-deﬁcient
mice are resistant to ConA-hepatitis, and (ii) in normal mice, ConA-
hepatitis is signiﬁcantly reduced by an anti-PS antibody [40]. Low-
molecular-weightheparins (LMWH)reportedly inhibit PS-dependent cell
adhesion [41]. Thus, we tested whether PS is involved in ConA-inducedFig. 9. Involvement of P-selectin (PS) in the HPA and hepatitis induced by ConA. (A) Effects o
ConA and LMWH (each 30 mg/kg) was injected, and 12 h later livers and blood were taken.
injected, and 15 min later S or anti-PS (1.6 mg/kg) was injected. Livers and blood were takHPAby using LMWH. As shown in Fig. 9A, LMWHmarkedly reduced both
the HPA and the levels of hepatitis makers induced by ConA. Next, we
examined the effect of anti-PS antibody on the maximal HPA that
precedesmaximal increases inAST andALT (see Fig. 1A). At the dose used
here, anti-PS antibody signiﬁcantly reduced both the HPA and hepatitis
markers inducedbyConAwithout adetectable effect on theplatelet count
in the circulation (Fig. 9B). These results suggest that P-selectin is involved
in both the HPA and hepatitis induced by ConA.
3.13. Electron-microscopic observations of livers
The above ﬁndings suggest that plateletsmay be protective against
ConA-hepatitis. Hence, ﬁnally, we observed platelet movement orf low-molecular-weight heparin (LMWH). Saline (S), ConA (30 mg/kg), or a mixture of
(B) Effects of monoclonal anti-mouse PS antibody (anti-PS). S or ConA (30 mg/kg) was
en 6 h after the second injection.
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purpose, we made electron-microscopic observations of livers taken
at two time-points, at 3 and 12 h after ConA injection: the former is an
early time in the liver 5HT increase (or HPA) (see Fig. 1A) and the
latter is the peak time for hepatitis markers (see Fig. 1A).
3.13.1. At 12 h after ConA treatment
As shown in Fig. 10A–C, hepatic lesions are evident at 12 h after
ConA injection, and LPS-pretreatment protects against such lesions. It
was notable that non-aggregated platelets could be detected in the
livers of mice pretreated with LPS, while aggregated platelets
frequently detected in the livers of mice not given LPS-pretreatment
(data not shown).
3.13.2. At 3 h after ConA treatment
As shown in Fig. 5B, LPS+ConA rapidly exacerbates ConA-
hepatitis in Pm-1-treated (i.e., platelet-depleted) mice. Platelets
were not detected in the livers of mice pretreated with Pm-1
(Fig. 10D). In these platelet-depleted mice, the rapid exacerbation of
ConA-hepatitis by LPS+ConAwas conﬁrmed by electron-microscopic
observations (Fig. 10D). Surprisingly; (i) expansion of Disse spaces
was noted in platelet-depleted mice, (ii) the cell membrane of
hepatocytes was ruptured, and (iii) the cell organelles (such as
mitochondria) of hepatocytes were scattered within the expanded
Disse spaces. Although congestion was evident in the liver at 3 h afterFig. 10. Electron-microscopicobservationsof livers frommice treatedwithConA, LPS, and/or Pm-
i.v.). Then, S or ConA (30 mg/kg, i.v.) was injected 2 h after the second injection. Livers were ta
Hepatocyteshaveabundantglycogengranules in their cytoplasm, indicating thenormal statusof t
after ConA injection (S→24 h S→2 h ConA→12 h sampling). Severe congestion within sinusoids
Aggregated platelets were also frequently detected (not seen in this ﬁeld). (C) LPS-protected liv
densityweremild indegree comparedwith those observed in B. In the sinusoidal lumen, several p
of ConA-hepatitis by platelet depletion (Pm-1→24 h LPS→2 h ConA→3 h sampling). Platelets we
evident. Cellmembraneofhepatocyteswas rupturedand thecell organelles ofhepatocyteswere s
after ConA-injection. Arrows indicate mitochondria leaked from hepatocytes into the expand
Congestion of liver was already evident, but the degree of hepatitis was mild compared
(not seen in this ﬁeld). (F) Effects of LPS (S→ 24 h LPS→ 2 h ConA→ 3 h sampling). ManyConA injection (Fig. 10E), the degree of hepatitis in such livers was
mild compared with those shown in Fig. 10B and D. In LPS-treated
mice, there were many platelets in contact with the endothelial cells
of sinusoids (Fig. 10C and F).
3.13.3. Platelet behaviors in liver
We previously reported that LPS and IL-1 induce translocation of
platelets into Disse spaces and their entry into hepatocytes [8]. In the
present study, we conﬁrmed such translocation of platelets into Disse
spaces (Fig. 11A and B) and their entry into hepatocytes in the livers of
mice treated with LPS followed by ConA (Fig. 11C).
4. Discussion
The present ﬁndings concerning the roles of platelets and/or
phagocytic (F4/80-positive) macrophages in ConA-hepatitis and in
the protective effect of LPS-pretreatment are summarized in Table 1.
As described previously [14–16] and conﬁrmed in the present study
(Fig. 4A), ConA-hepatitis depends on the presence of phagocytic
macrophages, this possibly being due to macrophages being required
to stimulate T-cells. In addition, our data suggest that P-selectin
(exogenous or injected) and endogenous IL-1 may be causally
involved in ConA hepatitis (Figs. 8A and 9), while endogenous IL-1
may be involved in the protective effect of LPS-pretreatment (Fig. 8B).
Incidentally; (i) LPS and ConA each induce a marked increase in liver1. Saline(S)or Pm-1was injected(s.c.), followed24 h later by injectionof Sor LPS (10 μg/kg,
ken 3 or 12 h after the last injection. (A) Normal liver (S→24 h S→2 h S→12 h sampling).
he liver. Itwashard todetectplatelets in the liver. (B)ConA-injured liver. Liverwas taken12 h
and decrease in electron density in the cytoplasm (asterisks) of hepatocytes were obvious.
er (S→24 h LPS→2 h ConA→12 h sampling). Both the congestion and decrease in electron
latelets (arrow)were detected, but aggregatedplateletswerenot detected. (D) Exacerbation
re detectedwithin neither sinusoidal lumens nor Disse spaces. Expansion of Disse spacewas
cattered in theexpandedDisse space, indicating severehepatitis hadoccurredwithinonly3 h
ed Disse space. (E) Liver 3 h after ConA injection (S→24 h S→2 h ConA→3 h sampling).
with those observed in B and D. Non-aggregated platelets were sometimes detected
platelets (arrows) are adhering to sinusoidal endothelial cells.
Fig. 11. Platelet behavior within the liver in mice treated with LPS+ConA. Livers were taken from the mice that provided the samples shown in Fig. 10F (i.e., S→24 h LPS→ 2 h
ConA→ 3 h sampling). (A and B) Several platelets (arrows) were seen in the Disse space (asterisks), indicating their translocation into Disse spaces from blood. (C) Platelets (arrow)
were sometimes detected in the cytoplasm of hepatocytes, indicating entry of platelets into hepatocytes from Disse spaces.
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indicating that the HPA induced by these substances is independent of
T-cells, and (ii) LPS by itself does not induce hepatocyte lesions in
normal mice or in mice depleted of PLTs and/or phagocytic
macrophages (data not shown), possibly because of its inability to
stimulate T cells. Our ﬁndings may seem very complicated. However,
cellular events may be multifactorial and dependent on timing in
actual hepatitis (i.e., actual hepatitis may consist of various aspects or
phases). So, it is quite possible that there is a phase in which platelets
and/or macrophages are exacerbating and/or protective. Our suppo-
sition is that the present ﬁndings may reﬂect such a phase, and may
help toward an understanding of that phase during the development
of hepatitis.
In the present study, platelet-depletion did not reduce the severity of
ConA-hepatitis (actually, there was if anything an exacerbation). In
addition, pretreatment with LPS (i.e., prior induction of HPA) markedly
reduced such hepatitis, suggesting that platelets are not causal, but
protective, against ConA-hepatitis. It should be noted that in mice
depleted of platelets (by either Pm-1 or MWReg30), LPS-pretreatment
greatly exacerbated ConA-hepatitis. These results support the idea that
the prior HPA induced by LPS is highly protective against ConA-
hepatitis. In other words, LPS induces “protective HPA” (Fig. 12).
However, in PLT-depleted mice, LPS+ConA induces lethal hepatitis
because: (i) LPS stimulates phagocytic (F4/80-positive)macrophages so
as to augment their interaction with T-cells, and (ii) such mice areTable 1
Effects of depletion of platelets (PLTs) and/or phagocytic macrophages (Mϕ*), with or
without prior LPS-treatment (pLPS), on the hepatitis and HPA induced by ConA. The
effects of ConA in normal mice were graded as +++. Figures that include relevant data
are indicated in the lowermost row for convenience.
Depletion None PLT Mϕ* PLT+
Mϕ*
None PLT Mϕ* PLT+
Mϕ*
pLPSa No No No No Yes Yes Yes Yes
Hepatitis +++ +++b ± − ± ++++c +++d −e
HPA +++ − ± − − − +++d −e
Figs 4A 4A 4B 5A 5B 5A 6
−: no signiﬁcant effect ±: minor effect +~++++: grades of effect.
a LPS by itself did not induce hepatitis in normal mice or in PLT- and/or Mϕ*-depleted
mice (data not shown).
b In PLT-depleted mice, ConA-induced hepatitis was slightly augmented (plasma AST
was signiﬁcantly increased) (Fig. 4A).
c In PLT-depleted mice, LPS+ConA induced lethal hepatitis (Fig. 5B).
d In Mϕ*-depleted mice, LPS+ConA induced both hepatitis and HPA, which were
similar to those induced in normal mice (Fig. 5A).
e In mice depleted of both PLTs and Mϕs*, LPS+ConA induced almost no hepatitis
(Fig. 6).unable tomanifest the “protective HPA”. It was a striking ﬁnding that in
platelet-depleted mice, LPS-pretreatment followed by ConA injection
induced severe rupture of the cell membranes of hepatocytes and
leakage of their constituents (Fig. 10D).
The precisemechanism underlying the above-mentioned protective
HPA remains to be clariﬁed. However, we speculate as follows on the
basis of a unique behavior shown by platelets. Platelets translocate into
Disse spaces (the spaces between vascular endothelial cells and
hepatocytes) in response to LPS, and cell-to-cell contact between
platelets and Kupffer cells may induce the migration of platelets from
sinusoidal spaces into Disse spaces [7]. Surprisingly, some of these
platelets enter hepatocytes [8]. Nevertheless, there is no visible damage
to the hepatocytes. In fact, many polysomes can be seen around those
platelets that are located within hepatocytes, suggesting an enhance-
ment of protein synthesis [8]. Such translocation of platelets and their
entry into hepatocytes have also been observed in the livers of mice
given an agonistic anti-Fas antibody [21], and we conﬁrmed theseFig. 12. Putative relationships between ConA-hepatitis and HPA, and effects of LPS.
Inferences and speculations made from the data are summarized in this ﬁgure. (i) ConA
stimulates interaction between T-cells and phagocytic macrophages (or Kupffer cells),
inducing hepatocyte injury and then resulting in causal HPA (platelet aggregation) via
leakageof platelet stimulants from injuredhepatocytes. This causal HPAmay formpart of a
vicious circle and thereby exacerbate the hepatitis. (ii) LPS stimulates interaction between
phagocytic macrophages and platelets, inducing protective HPA. (iii) Clo-lip-resistant,
macrophage-like cells may also be present. In mice depleted of phagocytic macrophages,
but not of platelets, LPS may stimulate the Clo-lip-resistant, macrophage-like cells and
promote their interaction with T-cells, inducing hepatocyte injury and triggering the
vicious circlementioned in (i).However, inmicedepletedofboth phagocyticmacrophages
and platelets, this pathway by itselfmay be tooweak to induce hepatitis. See text together
with Table 1 for further details.
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liver, in cooperationwithvariousother cells,mayplay important roles in
the initial defense against toxic materials or pathogens since, having
entered the blood via the digestive tract, these pass ﬁrst to the liver via
the portal vein. Platelets may assist in this hepatic defense after
gathering rapidly in the liver, although themechanism underlying their
protective effects remains to be elucidated.
Interestingly, despite the individual abilities of LPS and ConA to
induce HPA in normal mice, LPS-pretreatment+ConA induced no
detectable HPA (Fig. 5A) [this result was repeatedly conﬁrmed in
other experiments (Figs. 5B and 7B)]. However, in phagocytic
macrophage-depleted mice, LPS-pretreatment+ConA induced hepa-
titis and a marked HPA (Fig. 5A). Hepatocytes are known to contain or
produce some stimulants of platelets, such as ADP and prothrombin,
which induce platelet aggregation. Thus, hepatocytes, when injured
(as typically observed in Fig. 10D), may leak these substances [42].
Therefore, we speculate that in addition to the protective HPA (which
is reversible and phagocytic macrophage-dependent), there exists a
“causal HPA” (or platelet aggregation), which (i) is induced by the
platelet-stimulating substances leaked as a consequence of hepato-
cyte injury, and (ii) may be reduced by anti-P-selectin antibody or
blockade of P-selectin receptors (Fig. 12). The causal type of HPA may
be irreversible and thus result in aggregation of platelets, leading to an
impaired hepatic circulation [18], and subsequently to an exacerbated
hepatitis. Such a “vicious circle” (hepatocyte injury and release of platelet-
stimulating substances→platelet aggregation→additional hepatocyte
injury and further leakage of platelet-stimulating substances)may lead to
severe hepatitis. Indeed, in a hepatitis model induced by LPS+GalN, the
hepatic 5HT increase was markedly larger in livers displaying congestion
than in livers with no congestion [20]. We, therefore, speculate that in
normal mice, LPS-pretreatment can prevent ConA-induced hepatocyte
injury via a reversible prior protective HPA, and thus can prevent a
subsequent causal HPA (or platelet aggregation) being inducedby injured
hepatocytes (Fig. 12).
The experiments shown in Fig. 8 suggested that IL-1 may be
involved both causally in ConA-hepatitis and protectively follow-
ing LPS-pretreatment. Unfortunately, however, our exogenous
injection of IL-1 was not effective at protecting against ConA-
hepatitis. Thus, we speculate that in addition to IL-1, another
factor(s) may be involved in the protective effects of LPS or in the
effect of protective HPA. Thus, the protective mechanism remains
to be fully elucidated.
As described in Introduction, ConA-hepatitis is dependent on both
T-cells and macrophages. However, we noted that LPS+ConA (but
not LPS alone or ConA alone) induced hepatitis even in phagocytic
macrophage-depleted mice (Fig. 5A). This result suggests the possible
presence of Clo-lip-resistant macrophage-like (F4/80-negative and
not phagocytic) cells (Fig. 12). We speculate that in mice depleted of
phagocytic macrophages, but not platelets, LPS cannot induce any
protective HPA, and instead the LPS may stimulate the Clo-resistant,
macrophage-like cells and promote their interaction with T-cells,
thereby inducing hepatocyte injury and triggering the vicious circle
described above. However, in mice deﬁcient in both phagocytic
macrophages and platelets, this pathway by itself may be very weak
and therefore not able to induce hepatitis.
In conclusion, the ﬁndings made in the present study, on mice,
suggest that: (i) there are causal and protective types of HPA, (ii) the
causal type may involve platelet aggregation, and this may be induced
by platelet stimulants leaked from injured hepatocytes, (iii) the
protective type is phagocytic (or F4/80-positive) macrophage-
dependently inducible by prior low-dose administration of LPS, and
(iv) IL-1 is involved in both the causal and protective types. Thus, a
brief summary might be that LPS-pretreatment is able powerfully to
protect against such hepatitis via a prior induction of HPA, but in the
absence of platelets LPS-pretreatment strongly exacerbates ConA-
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